Established and Novel Approaches for Sarcopenia: Second Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Rehabilitation".

Deadline for manuscript submissions: 20 April 2025 | Viewed by 1228

Special Issue Editor


E-Mail Website
Guest Editor
Department of Physiology, National and Kapodistrian University of Athens, 11527 Athens, Greece
Interests: skeletal and cardiac muscle physiology; exercise physiology; clinical exercise physiology; molecular exercise physiology; mechanotransduction
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear colleagues,

We are pleased to announce the second edition of this Special Issue, “Established and Novel Approaches for Sarcopenia” (https://www.mdpi.com/journal/jcm/special_issues/9XI27I935X).

Sarcopenia represents the progressive age-related wasting of skeletal muscle mass accompanied by the loss of muscle strength. A decline in muscle strength and function is associated with an increased risk of adverse health outcomes, and sarcopenia patients are faced with mobility disorders, disability, a loss of independence, and reduced quality of life, while they are at a higher risk for morbidity (e.g., falls, bone fractures, and metabolic diseases, as skeletal muscle is one of the most important tissues for metabolic control) and mortality. Considering the growing elderly population and the increasing life expectancy, the prevalence of sarcopenia will escalate in the upcoming years. This provides the rationale for further characterizing the molecular mechanisms and abnormalities of sarcopenia, including abnormal energy metabolism, mitochondrial dysfunction, and myofiber type transition, as the basis for revealing and effectively treating its risk factors, thus developing efficient preventive and therapeutic strategies. Herein, we set up a Special Issue to incorporate papers focusing on established and novel approaches for sarcopenia, including, but not limited to, nutrition supplementation, pharmacological approaches, and physical exercise as interventions for sarcopenia. The Special Issue aims to present established, advanced, and novel insights for preventing or treating sarcopenia to decrease its comorbidities, and hence improve quality of life, increase life expectancy, and limit healthcare costs for these patients.

Dr. Anastassios Philippou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • sarcopenia
  • skeletal muscle wasting
  • muscle atrophy
  • myopathy
  • muscle protein catabolism
  • abnormal energy metabolism
  • mitochondrial dysfunction
  • myofiber type transition
  • morbidity
  • treatment strategies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1142 KiB  
Article
Evaluation of Five Screening Tools in Detecting Physical Frailty in Cirrhosis and Their Prognostic Role
by Eleni Geladari, Theodoros Alexopoulos, Larisa Vasilieva, Roxane Tenta, Iliana Mani, Vassilios Sevastianos and Alexandra Alexopoulou
J. Clin. Med. 2024, 13(17), 5169; https://doi.org/10.3390/jcm13175169 - 30 Aug 2024
Viewed by 928
Abstract
Background: Physical frailty (PF) is a syndrome of decreased physical function and reserves, preventing patients from coping with stressful events. PF screening tools in patients with liver cirrhosis (LC) can help evaluate the risk of complications and death. The aim of this [...] Read more.
Background: Physical frailty (PF) is a syndrome of decreased physical function and reserves, preventing patients from coping with stressful events. PF screening tools in patients with liver cirrhosis (LC) can help evaluate the risk of complications and death. The aim of this study was to assess the performance of five screening tools in detecting PF and their ability to predict 18-month mortality in LC. Methods: The Short Physical Performance Battery (SPPB), Fried frailty phenotype (FFP), Clinical Frailty Scale (CFS) and 6-Minute Walk Test (6MWT) were compared with the Liver Frailty Index (LFI) as the method of reference. Patients with an LFI ≥ 4.5, SPPB ≤ 8, FFP ≥ 3, CFS ≥ 6 points, and those walking <250 m, were considered frail. Results: A total of 109 consecutive patients with stable LC were included [63.3% male, median age 62 years, (IQR 52–70), MELD 9 (7–14.5), 46.8% with decompensated LC (DC)]. PF was present in 23.9%, 27.5%, 41.3%, 13.8%, and 28.4% as assessed by the LFI, SPPB, FFP, CFS, and 6MWT, respectively. Cohen’s kappa measurement of agreement of four of the tools with LFI was 0.568, 0.334, 0.439, and 0.502, respectively (p < 0.001 for each). Kaplan–Meier survival curves at 18 months showed higher mortality in frail patients compared to non-frail patients by any method (log rank p < 0.05). In the multivariate models, PF defined by any method emerged as an independent prognostic factor of 18-month mortality after adjustment for age, gender, and MELD-score. Conclusions: Patients characterized as frail by five screening tools were not identical. However, PF defined by either method was proven to be an independent poor prognostic factor for long-term mortality after adjustment for covariates. Full article
(This article belongs to the Special Issue Established and Novel Approaches for Sarcopenia: Second Edition)
Show Figures

Figure 1

Back to TopTop